To estimate the efficacy and toxicity of vinblastine and methotrexate for desmoid tumor in children with newly diagnosed or recurrent desmoid tumor who are not good candidates for treatment with surgery or radiation therapy. Patients with other fibroblastic lesions or other fibromatoses are NOT eligible for this study. The Primary Study Coordinator should be contacted if there is any question regarding eligibility.
Patients are eligible if there is gross residual disease after attempted surgical resection.
All patients must have measurable disease on MRI at the time of entry on study. Staging must include a gadolinium-enhanced MRI of the tumor to define the extent of disease. All patients must have normal renal, hepatic, and hematopoietic function as measured by routine serum chemistries and peripheral blood counts. Hemoglobin, white blood cell and platelet counts normal for age. Patients must be less than 19 years old at time of initial diagnosis.